Examine This Report on Antidepressant agent 5
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To judge a number of intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Main demo objectives had been To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyosit